Tag Archive for: BRCA
Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals June 9, 2026
- BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap June 9, 2026
- Ultrasound-Driven Cavitation Reprograms Drug Response and Immune Sensitivity in Neuroendocrine Prostate Cancer June 9, 2026
- Confirmed Efficacy of Rucaparib in BRCA-Mutated mCRPC June 9, 2026